Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Steven Cohen Reveals Two New Stock Picks, While Roberto Mignone Boosts Chimerix Inc. (CMRX) Stake

Page 1 of 3

The hedge fund industry as a whole did not perform particularly well in 2015, but there were a few investment vehicles that managed to greatly outperform the broader market. Steven Cohen’s family office Point72 Asset Management was one of those, as it gained almost 16% last year, while the S&P 500 Index closed the year in negative territory. Even though most hedge funds’ performance was not as fruitful as one might have anticipated during the less bullish market, it still pays off to track their moves and newest bets. For that reason, the following article will discuss three new 13G filings submitted with the SEC by billionaires Roberto Mignone and Steven Cohen. Two of the three 13Gs are filed by Cohen’s Point72, and may disclose two potential winners for 2016.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see more details here).

According to a Schedule 13G filing, Roberto Mignone’s Bridger Management LLC currently owns 2.97 million shares of Chimerix Inc. (NASDAQ:CMRX), which account for 6.4% of the company’s outstanding common stock. The position represents a large increase from the 307,782-share position revealed through the fund’s 13F filing for the third quarter. At the end of December, the biopharmaceutical company announced that its Phase 3 SUPPRESS trial of brincidofovir failed to meet its primary endpoint for the prevention of clinically significant cytomegalovirus (CMV) infection in patients undergoing hematopoietic cell transplantation (HCT). Chimerix Inc. (NASDAQ:CMRX)’s shares are down by nearly 75% since the announcement and some analysts believe that the stock represents a “post-blow-up opportunity”. In spite of the recent failure, the company intends to continue the separate trials testing brincidofovir in serious adenovirus infections and smallpox. Just recently, Piper Jaffray reiterated its ‘Overweight’ rating on the stock and lifted its price target to $18 from $11, citing increased confidence in brincidofovir’s trials in adenovirus, smallpox, and other infections. It is also important to note that Chimerix’s current share price assigns the company a value that is below its current cash balance. The strong insider buying registered at the company recently also suggests confidence in brincidofovir’s future potential among the firm’s top executives.

The number of hedge funds from our system with positions in Chimerix dropped to 17 from 21 during the third quarter (before the company announced the failure of the SUPPRESS trial). Even so, those investment managers amassed nearly 12% of the company’s outstanding shares. Jeremy Green’s Redmile Group lifted its position in Chimerix Inc. (NASDAQ:CMRX) by 53% during the third quarter to 1.07 million shares.

Roberto Mignone
Roberto Mignone
Bridger Management

Let’s head to the next two pages of this article, where we discuss the two filings submitted by successful money manager Steven Cohen.

Page 1 of 3

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!